HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study by Kelly, R S et al.
HPV testing as a triage for borderline or mild dyskaryosis
on cervical cytology: results from the Sentinel Sites study
RS Kelly
1, J Patnick
2, HC Kitchener
3 and SM Moss*,1 on behalf of the NHSCSP HPV Special Interest Group
4
1Cancer Screening Evaluation Unit, Institute of Cancer Research, Richard Doll Building, 15 Cotswold Road, Sutton, Surrey SM2 5NG, UK;
2NHS Cancer
Screening Programmes, Sheffield, UK;
3School of Cancer Studies and Enabling Sciences, University of Manchester, Manchester Academic Health
Science Centre, Manchester, UK
BACKGROUND: Earlier pilot studies of human papillomavirus (HPV) triage concluded that HPV triage was feasible and cost-effective.
The aim of the present study was to study the impact of wider rollout of HPV triage for women with low-grade cytology on
colposcopy referral and outcomes.
METHODS: Human papillomavirus testing of liquid-based cytology (LBC) samples showing low-grade abnormalities was used to select
women for colposcopy referral at six sites in England. Samples from 10051 women aged 25–64 years with routine call or recall
cytology reported as borderline or mild dyskaryosis were included.
RESULTS: Human papillomavirus-positive rates were 53.7% in women with borderline cytology and 83.9% in those with mild
dyskaryosis. The range between sites was 34.8–73.3% for borderline cytology, and 73.4–91.6% for mild dyskaryosis. In the single site
using both LBC technologies there was no difference in rates between the two technologies. The positive predictive value of an HPV
test was 16.3% for CIN2 or worse and 6.1% for CIN3 or worse, although there was considerable variation between sites.
CONCLUSION: Triaging women with borderline cytological abnormalities and mild dyskaryosis with HPV testing would allow
approximately a third of these women to be returned immediately to routine recall, and for a substantial proportion to be referred
for colposcopy without repeat cytology. Variation in HPV-positive rates results in differing colposcopy workload.
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The introduction of an organised cervical screening programme in
the United Kingdom in 1988 has led directly to a fall in the annual
number of new cases of invasive cervical cancer. The NHS cervical
screening programme has been estimated to prevent up to 3900
cases of cervical cancer (Sasieni et al, 1996; NHS, 2009) and save
approximately 4500 lives per year by 2030 (Peto et al, 2004).
Infection with high-risk human papillomavirus (HPV) is now
known to be a necessary aetiological factor in the development of
cervical cancer (Munoz et al, 2006). Those strains of HPV
associated with genital tract infection are subdivided into
high- and low-risk types, and of the former HPV 16 and 18 are
estimated to be responsible for over 70% of all cases of cervical
cancer (Howell-Jones et al, 2010). Testing liquid residue
from samples with borderline cytological abnormalities or mild
dyskaryosis for high-risk HPV DNA can identify those women who
are at risk of disease from those who have only a negligible risk of
high-grade CIN. A meta-analysis has found that the use of HPV
testing for triage in this way improved the accuracy for ASCUS
samples for an outcome of CIN2 or worse compared with repeat
cytology (Arbyn et al, 2004).
In 2001, the HPV/liquid-based cytology (LBC) pilot studies
reported on the feasibility of introducing HPV triage in the English
screening programme. Three sites converted to using LBC
and HPV triage with the Hybrid Capture 2 (HC2) assay for
women with borderline cytology or mild dyskaryosis. Initially all
HPV-positive women were referred to colposcopy, whereas HPV-
negative women were re-tested at 6 months and referred to
colposcopy if found to be HPV-positive or cytology of mild
dyskaryosis or worse. Readings greater than three times the kit
derived cutoff (Co) value in relative light units (RLUs) were
considered positive (43RLU/Co). The protocol was amended in
two sites, where HPV-positive women aged under 35 years were
re-tested at 6 months and only referred to colposcopy if HPV
infection and/or cytological abnormality persisted. The results of
the pilot study suggested that although HPV triage decreased the
number of repeat cytology tests and reduced the time taken to
return women to routine recall, it resulted in a large increase in
referrals to colposcopy. Nevertheless, not only was HPV triage
feasible and acceptable to women but also the results of an
economic analysis concluded that it was cost-effective, both in
terms of quality and of life years saved (Legood et al, 2006; Moss
et al, 2006).
In 2007, the ‘Sentinel sites’ protocol was implemented,
representing B10% of the English cervical screening programme.
The sites included two from the original pilots (Bristol and Norfolk
and Norwich), and four additional ones (Liverpool, Manchester,
Sheffield and Northwick Park). An agreed protocol for the use of
HPV triage for women with borderline or mild dyskaryosis was
followed.
Received 4 May 2011; revised 20 July 2011; accepted 26 July 2011;
published online 6 September 2011
*Correspondence: Dr SM Moss; E-mail: sue.moss@icr.ac.uk
4See Appendix.
British Journal of Cancer (2011) 105, 983–988
& 2011 Cancer Research UK All rights reserved 0007– 0920/11
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sThe evaluation of this project aimed to provide information on the
likely effect of national rollout, including rates of referral to
colposcopy, and the positive predictive value (PPV) of this approach.
MATERIALS AND METHODS
Samples from women, aged 25–64 years, undergoing routine call
or recall cytology at the six sites reported as borderline or mild
dyskaryosis, were included in the protocol.
Cytology was liquid based; three sites used ThinPrep LBC
(Hologic, Bedford, MA, USA), two sites used BD SurePath LBC
(Beckton Dickinson, Franklin Lakes, NJ, USA) and one site used
both the technologies. Samples reported as borderline or mild
dyskaryosis were sent to one of two HPV testing laboratories
serving all six of the sentinel sites. The Qiagen HC2 (Crawley,
England) assay was used, with a cut-off of 2RLU/Co to determine
positivity (Sargent et al, 2010).
The protocol is shown in Figure 1. Women who tested negative for
HPV were returned to routine recall at 3 or 5 years, depending on
age; those who were HPV-positive were referred to colposcopy.
Women who appeared normal at colposcopic inspection and those
found to have no CIN on biopsy were returned to routine recall.
Women diagnosed with CIN1 on biopsy and who were not treated
underwent a 12-month surveillance cytology. Women with CIN2 or
worse were treated and followed up with a test of cure protocol. This
comprised of repeat cytology at 6 months and a reflex HPV test in
those with negative cytology, with referral to colposcopy if either
was positive; all other women were returned to routine recall at 3
years (regardless of age). The results of the analysis of the test of cure
protocol will be presented elsewhere, as will be data on cost-
effectiveness. Anonymous data on relevant cytology HPV tests, RLU
values, biopsy, treatment and histology were collected, together with
information on management and reasons for non-attendance.
The study took place between 1 January 2008 and 1 April 2009.
Follow-up data were collected until September 2009, with addi-
tional data requested for those individual women with outstanding
cytology and/or colposcopy outcomes. Statistical analysis was
conducted using STATA version 10 (Stata Corporation, College
Station, TX, USA). Age standardisation used 5-year age groups,
standardised to the European standard population (Waterhouse
et al, 1976).
HPV +ve
CIN2/3
Colposcopy
No repeat cytology
CIN1
Treatment
HPV –ve
No treatment
Colposcopy
Cytology follow-up
according to national
guidelines
Cytology at 6
months
2Cytology at 12
months with or
without colposcopy
(local preference)
Normal Abnormal
33-year recall
HPV –ve HPV +ve
Routine 3- or 5-year recall
(depending on age <50 or
50 years)
1First borderline or first mild dyskaryosis
Borderline/mild with
negative colposcopy
no biopsy
or biopsy with no CIN
Figure 1 Study protocol.
1If sample is inadequate for the HPV test, recall for 6-month repeat cytology/HPV test or refer to colposcopy, depending on
local referral practice.
2Follow-up after 12-month cytology only, should follow normal NHSCSP protocols.
3Women X50 years who have normal cytology
at 3 years will then return to 5-yearly routine recall. NB Women who reach 65 years still require to complete the protocol, otherwise need to comply with
the national guidelines.
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Screening Evaluation Unit.
RESULTS
A total of 10051 women entered the protocol; 6507 (64.7%) had
an initial borderline test and 3544 (35.3%) had initial mild
dyskaryosis.
HPV-positive rates
Of these 10051 women, 6470 (64.4%) tested positive for high-risk
HPV, 53.7% of those with a borderline test and 83.9% of those with
mild dyskaryosis. There was a highly significant decreasing trend
in HPV-positive rate with increasing age (Po0.0001) in both
categories. Less than 2% of HPV-positive women had an RLU
value of between 2 and 3. The profiles of the study participants are
shown in Table 1.
The HPV-positive rates at the six sites ranged from 34.8% to
73.3% for women with borderline cytology, and from 73.4% to
91.6% for women with mild dyskaryosis. (Table 2) These
differences remained after the rates were standardised for age.
Overall the HPV-positive rate was higher in sites using ThinPrep
LBC than in those using BD SurePath LBC; 68.7% and 61.7%,
respectively, (Po0.0001). The difference remained after adjust-
ment for age group and initial cytology result. LBC technology was,
however, confounded by site, and it was therefore not possible to
determine whether this difference was due to variation in the
reporting of cytology between sites. In the only site which used
both technologies there was no significant difference in positive
rates between the two.
Colposcopy following a positive HPV test
At least 6 months follow-up was available for all 6470 HPV-
positive women, of which 5838 (90.2%) attended colposcopy.
Attendance varied from 96.2% to 81.4% between sites. No
information was available on the remaining 632 who failed to
attend.
Table 3 shows the outcome at colposcopy in the 5838 women
who attended. The proportion of women who were negative at
colposcopy, due either to a negative biopsy or to a negative
colposcopic assessment, resulting in no biopsy being performed,
was significantly higher in women with initial borderline cytology
than in women with mild dyskaryosis, 59.9% and 48.3%,
respectively, (Po0.0001). Overall, 29% of these had no biopsy.
There were 298 colposcopies for which information on biopsy
type was not available or was coded as ‘other’. Nearly 19% (1093
out of 5838) of women who attended colposcopy were reported as
not undergoing biopsy, although 16.0% (175 out of 1093) of these
women had a recorded diagnosis of CIN1. Almost 63% (3631 out
of 5838) of all women who attended colposcopy underwent a
diagnostic punch biopsy, of which 49.0% (1778 out of 5838) were
negative for CIN. Excision biopsy by LLETZ was reported in 196
women, of whom only 114 (58.2%) were found to have CIN2 or
worse, and almost 30% (56) were negative for CIN. A further 442
women were known to have had a biopsy, but the type was not
specified.
The type of procedure performed at colposcopy varied greatly
by centre, with the percentage of women not undergoing biopsy
varying from 65.9% to 2.7%, and the proportion undergoing punch
biopsy varying from 26.5% to 95%.
Positive predictive value
The PPV of a positive HPV test for detecting high-grade CIN in
women who attended colposcopy was 6.1% for CIN3 or worse and
16.3% for CIN2 or worse (Table 3). The PPV for CIN3 or worse was
slightly, but significantly, higher in women with initial borderline
cytology than in women with initial mild dyskaryosis (6.7% vs
5.4%; P¼0.03); but this was not observed for CIN2 or worse. There
was a highly significant decreasing trend in the PPV for CIN2 or
Table 1 HPV-positive rates by age group and initial cytology result
Borderline Mild Total
Age group Number of women HPV+ n (%) Number of women HPV+ n (%) Number of women HPV+ n (%)
25–34 3121 2144 (68.7) 2203 1964 (89.2) 5324 4108 (77.2)
35–49 2783 1165 (41.9) 1129 869 (77.0) 3912 2034 (52.0)
50–64 603 187 (31.0) 212 141 (66.5) 815 328 (40.2)
Total 6507 3496 (53.7) 3544 2974 (83.9) 10051 6470 (64.4)
Abbreviation: HPV¼human papillomavirus.
Table 2 HPV-positive rates by site and initial cytology
Borderline Mild Total
Site n HPV +ve (%) n HPV +ve (%) n HPV +ve (%)
A 789 455 (57.7) 420 372 (88.6) 1209 827 (68.4)
B 643 224 (34.8) 523 384 (73.4) 1166 608 (52.1)
C 2557 1111 (43.4) 1507 1232 (81.8) 4064 2343 (57.7)
D 663 406 (61.2) 557 500 (89.8) 1220 906 (74.3)
E 1263 866 (68.6) 404 370 (91.6) 1667 1236 (74.1)
F 592 434 (73.3) 133 116 (87.2) 725 550 (75.9)
C (Thinprep LBC) 1188 543 (47.7) 798 669 (83.8) 1986 1212 (61.0)
C (BD Surepath LBC) 426 216 (50.7) 241 204 (84.6) 667 420 (63.0)
Total (Thinprep LBC) 3903 2270 (58.2) 2179 1911 (87.7) 6082 4181 (68.7)
Total (BD Surepath LBC) 1661 874 (52.6) 897 704 (78.5) 2558 1578 (61.7)
Abbreviations: HPV¼human papillomavirus; LBC¼liquid-based technology. Technology not known for 943 borderline and 468 mild samples.
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sworse with increasing age group (Po0.0001), which was observed
both in women with initial borderline and initial mild dyskaryosis.
The PPV of HPV for detecting high-grade disease varied by
centre (Table 4); the PPV for CIN2 or worse ranged from 9.3% to
21.5% and for CIN3 or worse from 2.5% to 11.5% for women with
borderline changes at cytology. For women with mild dyskaryosis,
the PPV for CIN2 or worse ranged from 9.1% to 33.0% and for
CIN3 or worse from 2.5% to 15.2%. Standardising for age and for
the ratio of borderline to mild tests did not reduce this variation.
DISCUSSION
This study is indicative of the impact of rolling out of HPV triage,
in terms of colposcopy referral and detection of CIN2þ. The
principal findings are that referral rates following triage varied
across clinical sites, and the proportion of referred women with
CIN2þ (PPV) varied. The strength of this study was its real-life
response to HPV triage as routine NHS practice across six sites in
England. The main limitation of this study was that its observa-
tional nature resulted in a number of women not being managed
according to protocol, and follow-up was, therefore, incomplete at
the time of end of data collection. We believe, however, that the
results for the large majority of women who did attend following
referral are representative of the cohort as a whole.
The HPV-positive proportion in the current study was higher
than that observed in the pilot studies of 2003–2004. As a result,
referral to colposcopy of 64% was significantly higher than that
observed with both the initial (48%) and the revised (38%)
protocol of the pilot studies, despite women who were HPV-
negative being returned immediately to routine recall. The PPVs of
HPV for CIN2 or worse and CIN3 or worse were lower in the
present study than those observed in the earlier pilot studies; 6.1%
vs 8.3% for CIN3þ (P¼0.004) and 16.3% vs 20.0% for CIN2þ
(P¼0.0014). The attendance rate for colposcopy was high (90.2%),
and greater than that of 72% seen in a similar UK-based study for
women with a borderline cytology result, a positive HPV test or
both (Cuzick et al, 2003). The higher HPV-positive rates observed
in this study are not readily explained by the lower cut-off for a
positive test of 2RLU/Co compared with 3RLU/Co in the earlier
studies, as the proportion of women with RLU/Co between 2.0 and
3.0 was small. They may be due, in part, to changes in the
demographics of the populations, and changes in sampling
technique or perhaps more likely, due to cytological classification.
The HPV-positive rates observed in this study, overall, are also
higher than those observed in other studies. In the UK-based
ARTISTIC trial, which had a high rate of borderline cytology, the
HPV-positive rate was 31.1% for borderline cytology and 69.9% for
mild dyskaryosis (Kitchener et al, 2006). A meta-analysis (Arbyn
et al, 2009) found an average HPV-positive rate of 43% (95% CI:
40–46%) for women with ASCUS/ASC-US (broadly comparable to
borderline cytology) and 76% (95% CI: 71–81%) for women with
LSIL (broadly comparable to mild dyskaryosis).
Of importance was the observed difference between sites in
HPV-positive rates. The threshold used to determine borderline
and mild dyskaryosis test results will vary between laboratories.
According to a 3-year average from the NHSCSP screening returns
(KC61 part B: 2006–07, 2007–08 and 2008–09), the two sites with
the lowest rate of HPV-positive tests classified a higher percentage
of all samples taken as borderline or worse than do the other sites,
suggesting that they may be including samples in their borderline
changes category that other laboratories would class as negative.
Heterogeneity in HPV-positive rates between studies has also
been observed in a meta-analysis of studies of triage in women
with ASCUS/LSIL cytology (Arbyn et al, 2009). The rates in the
current study are within the observed range of this meta-analysis.
Table 3 Results of follow-up of HPV-positive women
Inadequate/unknown/
other, n (%) Negative, n (%)
Positive
cytology, n (%) CIN1, n (%) CIN2, n (%) CIN3+, n (%) Total, n (%)
BL
25–34 64 (3.3) 1091 (56.6) 45 (2.3) 394 (20.4) 193 (10.0) 142
a (7.4) 1929 (100.0)
35–49 30 (2.8) 679 (64.0) 26 (2.5) 173 (16.3) 88 (8.3) 65 (6.1) 1061 (100.0)
50–64 8 (4.7) 124 (72.5) 3 (1.8) 27 (15.8) 4 (2.3) 5 (2.9) 171 (100.0)
Total 102 (3.2) 1894 (59.9) 74 (2.3) 594 (18.8) 285 (9.0) 212 (6.7) 3161 (100.0)
Mild
25–34 71 (4.1) 821 (46.9) 62 (3.5) 468 (26.7) 217 (12.4) 111 (6.3) 1750 (100.0)
35–49 27 (3.4) 392 (49.2) 25 (3.1) 236 (29.6) 87 (10.9) 30 (3.8) 797 (100.0)
50–64 3 (2.3) 80 (61.5) 5 (3.8) 31 (23.8) 8 (6.2) 3 (2.3) 130 (100.0)
Total 101 (3.8) 1293 (48.3) 92 (3.4) 735 (27.5) 312 (11.7) 144 (5.4) 2677 (100.0)
Total 203 (3.5) 3187 (54.6) 166 (2.8) 1329 (22.8) 597 (10.2) 356 (6.1) 5838 (100.0)
Abbreviations: BL¼borderline; CIN¼cervical intraepithelial neoplasia; HPV¼human papillomavirus.
aIncludes three invasive cancers.
Table 4 PPV of colposcopy by site
Borderline Mild Total
Site
No. attending
colposcopy
PPV
CIN2+
PPV
CIN3+
No. attending
colposcopy
PPV
CIN2+
PPV
CIN3+
No attending
colposcopy
PPV
CIN2+
PPV
CIN3+
A 430 16.5 7.4 354 21.8 7.6 784 18.9 7.5
B 178 11.2 6.2 317 9.1 3.5 495 9.9 4.4
C 978 11.6 5.0 1104 15.9 4.8 2082 13.9 4.9
D 355 9.3 2.5 440 10.9 2.5 795 10.2 2.5
E 803 21.5 7.8 350 25.4 7.1 1153 22.7 7.6
F 417 20.9 11.5 112 30.0 15.2 529 23.4 12.3
Abbreviations: CIN¼cervical intraepithelial neoplasia; PPV¼positive predictive value.
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control provided by the National External Quality Assessment
Service and by the Scottish HPV reference laboratory, in addition
to internal quality assurance (QA) procedures with retesting of 2%
of all samples. There was variation in the PPV between the sites
tested by each HPV testing laboratory.
The lower PPV values observed in this study may be a
consequence of higher HPV-positive rates, if these are not related
to a higher prevalence of CIN. The differences between sites may
reflect the different rates of cytological abnormality and HPV
positivity in the sites participating. Because this was a pragmatic
study, there was no additional QA of the colposcopy, but all
colposcopists taking part are BSCCP certified and take part in the
NHSCSP QA programme. There was considerable variation in rates
of punch biopsy, which implies variation in local practice and in
part explains the variation in rates of high-grade CIN. In 29% (997
out of 3187) of the colposcopy results reported as negative, no
biopsy was taken, but there is no evidence that the variation in
PPV between sites is related to the variation in biopsy rate.
The variation in the PPV of a positive HPV test is also reflected
in the literature; estimates range from a PPV of 8.3% (Guyot et al,
2003) to 58.1% (Rebello et al, 2001) for ASCUS and CIN2þ and
8.4% (Bergeron et al, 2000) to 54.5% (Rebello et al, 2001) for LSIL
and CIN2þ. A meta-analysis has found a pooled PPV of 22.3% for
ASCUS and 27.3% for LSIL (Arbyn et al, 2005). The PPV of an
HPV test for high-grade disease appears more dependent on age
than on the grade of cytology, which may be indicative that high-
risk HPV is more important than whether a sample is classified as
borderline or mild.
The results of the original pilot studies suggested that referring
all HPV-positive women to colposcopy led to an earlier detection
of CIN2þ compared with standard practice, however this effect
was not observed for CIN3þ. The revised protocol for women
aged 25–34 years adopted for part of these studies reduced the
colposcopy workload somewhat, but 75% of women remained
HPV-positive at 6 months, and such a policy increased the number
of repeat smears and the risk of loss to follow-up. The UK-based
TOMBOLA trial (TOMBOLA Group, 2009a,b,c) recommended a
policy of surveillance rather than triage for two reasons; the first
was that some CIN2þ will regress with time and the second was
that they identified a high proportion of HPV-negative CIN 2.
HPV-negative CIN2 is, however, probably of little clinical
significance. The high rate of compliance with colposcopy
indicates that triage is acceptable to women, and the ability to
return to recall not only 50% of those referred to colposcopy but
also the 35% of women who were HPV-negative are both
significant benefits (TOMBOLA Group, 2009a,b,c).
Although the HPV-positive rate in women with mild dyskaryosis
is high, the negative predictive value of an HPV test in these
women is over 96% (Moss et al, 2006), and the use of triage allows
16% of these women to be returned to routine recall.
The difference in HPV-positive rates between the centres
involved in this project highlights the inter-laboratory variation
in grade classification, which will be reflected in any wider rollout
of HPV triage around the country, in terms of rates of referral to
colposcopy. It also highlights the need for efficient management of
HPV-positive women found to be negative at colposcopy. The PPV
for CIN2 or worse, 16%, was relatively low, which suggests that
although HPV triage is a useful tool for returning women at low
risk to routine recall, further refinement of triage should be
considered to improve PPV without loss of sensitivity. This could
exploit HPV genotyping and biomarkers, both of which have been
shown to be capable of improving specificity (Szarewski et al,
2008), with the need to avoid increasing reporting times.
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